STOCK TITAN

Seaport Therapeutics Names Lauren White as Chief Financial Officer

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Lauren White has been appointed as Chief Financial Officer of Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on neuropsychiatric medicines. White previously served as CFO at ImmunoGen, where she played a important role in the company's $10.1 billion acquisition by AbbVie in 2024 and the commercial launch of ELAHERE®. With over 22 years of experience, White's background includes positions at C4 Therapeutics, Novartis, Boston Consulting Group, and General Electric. She holds a BS from Boston College and an MBA from Harvard Business School.

Lauren White è stata nominata Chief Financial Officer di Seaport Therapeutics, un'azienda biofarmaceutica in fase clinica focalizzata su medicinali neuropsichiatrici. White ha precedentemente ricoperto il ruolo di CFO presso ImmunoGen, dove ha avuto un ruolo importante nell'acquisizione della società da parte di AbbVie per 10,1 miliardi di dollari nel 2024 e nel lancio commerciale di ELAHERE®. Con oltre 22 anni di esperienza, il background di White include posizioni in C4 Therapeutics, Novartis, Boston Consulting Group e General Electric. Ha conseguito una laurea alla Boston College e un MBA alla Harvard Business School.

Lauren White ha sido nombrada Directora Financiera de Seaport Therapeutics, una compañía biofarmacéutica en etapa clínica enfocada en medicamentos neuropsiquiátricos. White anteriormente se desempeñó como CFO en ImmunoGen, donde tuvo un papel importante en la adquisición de 10.1 mil millones de dólares por parte de AbbVie en 2024 y en el lanzamiento comercial de ELAHERE®. Con más de 22 años de experiencia, el historial de White incluye posiciones en C4 Therapeutics, Novartis, Boston Consulting Group y General Electric. Obtiene una licenciatura de Boston College y un MBA de Harvard Business School.

로렌 화이트가 신경정신 의약품에 집중하는 임상 단계의 생명공학 회사인 Seaport Therapeutics의 최고 재무 책임자로 임명되었습니다. 화이트는 이전에 ImmunoGen의 CFO로 재직하며, 2024년에 AbbVie의 101억 달러 인수 및 ELAHERE®의 상업 출시에 중요한 역할을 했습니다. 22년 이상의 경력을 지닌 화이트는 C4 Therapeutics, 노바티스, 보스턴 컨설팅 그룹, 제너럴 일렉트릭 등에서 일한 경력을 가지고 있습니다. 그녀는 보스턴 대학교에서 학사를, 하버드 비즈니스 스쿨에서 MBA를 받았습니다.

Lauren White a été nommée Directrice financière de Seaport Therapeutics, une entreprise biopharmaceutique en phase clinique axée sur les médicaments neuropsychiatriques. White a précédemment été CFO chez ImmunoGen, où elle a joué un rôle clé dans l'acquisition de 10,1 milliards de dollars par AbbVie en 2024 et le lancement commercial de l’ELAHERE®. Avec plus de 22 ans d'expérience, le parcours de White comprend des postes chez C4 Therapeutics, Novartis, Boston Consulting Group et General Electric. Elle est titulaire d'une licence du Boston College et d'un MBA de la Harvard Business School.

Lauren White wurde zur Chief Financial Officer von Seaport Therapeutics ernannt, einem biopharmazeutischen Unternehmen in der klinischen Phase, das sich auf neuropsychiatrische Medikamente spezialisiert hat. Zuvor war White CFO bei ImmunoGen, wo sie eine wichtige Rolle bei der 10,1 Milliarden Dollar schweren Übernahme durch AbbVie im Jahr 2024 und dem kommerziellen Launch von ELAHERE® spielte. Mit über 22 Jahren Erfahrung umfasst Whites beruflicher Werdegang Positionen bei C4 Therapeutics, Novartis, Boston Consulting Group und General Electric. Sie hat einen Bachelor-Abschluss vom Boston College und einen MBA von der Harvard Business School.

Positive
  • Key executive from ImmunoGen's successful $10.1B acquisition by AbbVie joins the company
  • Experienced CFO with track record in successful commercial drug launch (ELAHERE®)
  • Strong background in M&A, strategic partnering, and financial planning
Negative
  • None.

Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations

BOSTON--(BUSINESS WIRE)-- Seaport Therapeutics (“Seaport or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its acquisition by AbbVie (NYSE: ABBV) for $10.1 billion in 2024.

“I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatment of anxiety, depression and other neuropsychiatric disorders,” said Daphne Zohar, Founder and Chief Executive Officer at Seaport. “Her strong leadership background in biotech finance will be valuable as we chart an efficient path to delivering these important new medicines to patients.”

Ms. White brings over 22 years of corporate finance, accounting, strategic partnering and investor relations expertise to Seaport. As the CFO at ImmunoGen, Ms. White played a key role on the internal deal team, conducting thorough analysis and due diligence during the M&A process with multiple potential buyers, which ultimately led to the successful acquisition of the company by AbbVie. Additionally, Ms. White helped to maximize the successful commercial launch of ELAHERE®, a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. Before joining ImmunoGen, Ms. White served as Chief Financial Officer, Treasurer, and Principal Accounting Officer at C4 Therapeutics (NASDAQ: CCCC), where she was responsible for developing and leading the company's financial, capital, and procurement strategies.

Prior to that, Ms. White held roles of increasing responsibility at Novartis (NYSE: NVS), most recently serving as Global Head of Financial Planning and Analysis for the Novartis Institutes for BioMedical Research (NIBR), where she drove financial strategy and business planning. Before Novartis, Ms. White held strategy and marketing roles with Boston Consulting Group and General Electric. Ms. White received a BS from the Carroll School of Management at Boston College and earned an MBA from Harvard Business School.

“I’m excited to join the outstanding team at Seaport at this important stage of development,” said Ms. White. “I look forward to working with our team and collaborators to leverage our recent financial progress and support Seaport’s mission to deliver meaningful medicines that positively impact the lives of patients and their families.”

About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.

Shannon Costello

Seaport Therapeutics

publicrelations@seaporttx.com

Source: Seaport Therapeutics

FAQ

When was ImmunoGen (IMGN) acquired by AbbVie?

ImmunoGen (IMGN) was acquired by AbbVie for $10.1 billion in 2024.

What was Lauren White's role in ImmunoGen (IMGN) before joining Seaport?

Lauren White served as Chief Financial Officer at ImmunoGen (IMGN), where she played a key role in the M&A process with AbbVie and helped maximize the commercial launch of ELAHERE®.

What was the acquisition value of ImmunoGen (IMGN)?

ImmunoGen (IMGN) was acquired by AbbVie for $10.1 billion.

ABBVIE INC.

NYSE:ABBV

ABBV Rankings

ABBV Latest News

ABBV Stock Data

306.72B
1.77B
0.1%
73.45%
1.14%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NORTH CHICAGO